Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
Launched by DUKE UNIVERSITY · Mar 25, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The IRIS-CKD trial is a study aimed at improving how doctors screen for chronic kidney disease (CKD) in people who have type 2 diabetes (T2D). This study is important because many individuals with diabetes may not get the kidney checks they need, which could help catch problems early. The goal is to make sure that more patients receive regular tests that can help monitor their kidney health.
To be part of this study, participants need to be adults aged 65 to 74 who have type 2 diabetes and have seen a primary care doctor in the last two years. Importantly, they should not have been diagnosed with chronic kidney disease already. If eligible, participants will help the healthcare system identify and improve the ways that kidney health is monitored for those with diabetes. The trial is not yet recruiting participants, but it aims to make a big difference in care for individuals with diabetes and their kidneys.
Gender
ALL
Eligibility criteria
- • Screening Program-
- Inclusion Criteria:
- • Adults with type 2 diabetes (T2D)
- • Receiving primary care within the healthcare system, Primary Care Provider (PCP) visit within the past 24 months (any PCP provider, including APP).
- • Lack of estimated glomerular filtration rate (eGFR) and/or urine albumin- creatinine ratio (UACR) measurement in the prior 15 months within the EHR
- Exclusion Criteria:
- • • Chronic kidney disease (CKD) diagnosis
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nashville, Tennessee, United States
Duluth, Minnesota, United States
New Orleans, Louisiana, United States
Durham, North Carolina, United States
Murray, Utah, United States
Temple, Texas, United States
Patients applied
Trial Officials
Neha Pagidipati, MD
Principal Investigator
Duke University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported